AshHill is a private investment firm with a specialized focus on the biomedical sector and participating in its portfolio companies in active management roles, as well as scientific and support services. Its mission is to discover, analyze and invest in start-up, seed-stage and established companies that are working to develop medical innovations.
The firm’s leadership, including physicians, researchers, business professionals and entrepreneurs bring experience in the establishment, development, management and sale of pharmaceutical companies to optimize investments and help bring pharmaceuticals and medical devices through the regulatory process and into the marketplace.
Combination of experience
Ash Hill’s leadership team offers expertise in the biomedical industry as well as extensive experience growing biomedical companies from start-up and seed-stage to mature companies. We combine that with business and investing experience to offer our investors and our invested companies a proven track record.
Active management role
AshHill takes active management roles in its portfolio companies. The firm’s leadership team members take board seats and key leadership positions to offer their business experience and industry knowledge to the companies they are working alongside. For example, Dr. Peter Milner is currently serving as CEO of Heart Metabolics, Dave Buffenbarger is serving as CFO and VP of Finance for Armetheon, Inc., and Steven R. Smith is on the board of directors at Heart Metabolics.
Focus on medical need
The AshHill team evaluates each investment opportunity on specific criteria that includes the financial potential of the company. But the approach goes beyond the numbers; AshHill Biomedical Investments is also focused on areas of unmet medical need. With clinical expertise, the team is able to compare a potential investment company’s methodology to existing treatments, diagnostic tools or prevention methods.
By recognizing truly breakthrough technologies, we identify companies that have the potential to improve the health and wellness of under-served populations or address issues that are being ignored by larger companies. The regulatory track success of our portfolio companies demonstrates our ability to identify companies that have a strong likelihood of success in their endeavors.
Menlo Park, CA – February 5, 2015 – Armetheon, Inc., a cardiovascular disease-focused, clinical stage, specialty biopharmaceutical company, today announced the successful closing of $24.3 million in Series B financing. The financing was co-led by Hercules Bioventure...read more
Menlo Park, CA – August 28, 2014 --- Armetheon, Inc. (www.armetheon.com), a biopharmaceutical company focused on developing novel mid- to late-stage cardiovascular drug candidates, today announced that it has raised $7.0 million in its first round of financing. The...read more
Cincinnati, Ohio – AshHill Biomedical Investments, a U.S.-based private investment firm specializing in biomedical opportunities, announced several of its ventures recently passed significant FDA approval hurdles – including Orphan Drug Designation for a medication...read more